Skip to content
10-Q

Quarterly Report

BIOCRYST PHARMACEUTICALS INC BCRX

0001628280-26-031238

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 254.16M sh
Shares Diluted Q1 2026 · Mar 31, 2026 242.26M sh
Shares Diluted Q1 2026 · Mar 31, 2025 215.26M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$61.79M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$27.52M
Long Term Debt Q1 2026 · Mar 31, 2026 $395.2M
Long Term Debt Q1 2026 · Dec 31, 2025 $0
Short Term Investments Q1 2026 · Mar 31, 2026 $66.81M
Short Term Investments Q1 2026 · Dec 31, 2025 $185.01M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $171.59M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $89.74M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $105.19M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$553.84M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$119.15M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$451.93M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$475.93M
Current Liabilities Q1 2026 · Mar 31, 2026 $195.39M
Current Liabilities Q1 2026 · Dec 31, 2025 $196.07M
Total Liabilities Q1 2026 · Mar 31, 2026 $1.02B
Total Liabilities Q1 2026 · Dec 31, 2025 $633.31M
Current Assets Q1 2026 · Mar 31, 2026 $373.63M
Current Assets Q1 2026 · Dec 31, 2025 $404.35M
Total Assets Q1 2026 · Mar 31, 2026 $465.05M
Total Assets Q1 2026 · Dec 31, 2025 $514.16M
Eps Diluted Q1 2026 · Mar 31, 2026 −$2.98
Eps Diluted Q1 2026 · Mar 31, 2025 $0.00
Eps Basic Q1 2026 · Mar 31, 2026 −$2.98
Eps Basic Q1 2026 · Mar 31, 2025 $0.00
Sga Expense Q1 2026 · Mar 31, 2026 $94.55M
Sga Expense Q1 2026 · Mar 31, 2025 $82.47M
Rd Expense Q1 2026 · Mar 31, 2026 $60.32M
Rd Expense Q1 2026 · Mar 31, 2025 $37.27M
Net Income Q1 2026 · Mar 31, 2026 −$721.81M
Net Income Q1 2026 · Mar 31, 2025 $32K
Operating Income Q1 2026 · Mar 31, 2026 −$701.6M
Operating Income Q1 2026 · Mar 31, 2025 $21.23M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $5.38M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $4.57M